RxDoctor Payments Data

Lindsay Garinger, APRN

Family · Enid, OKNPI 1891233326

Payments from drug & device makers

$780in general payments, 2019–2025

Across 49 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$212
  • Otsuka America Pharmaceutical, Inc.$154
  • Amgen$85
  • AbbVie$64
  • Novo Nordisk$63
  • Boehringer Ingelheim$61
  • plus $142 from 7 others

What the payments were for

  • Food & beverage$780100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$780 in reported general payments places this provider in the 65th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$51,963
Medicare patients
140
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin61$69,022
TrulicityDulaglutide34$54,275
OzempicSemaglutide27$49,534
JanuviaSitagliptin Phosphate33$36,729
FarxigaDapagliflozin Propanediol24$18,804
EliquisApixaban17$17,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,552
Tresiba Flextouch U-100Insulin Degludec12$8,002
Breo ElliptaFluticasone/Vilanterol14$5,220
SymbicortBudesonide/Formoterol Fumarate22$4,913
Dexlansoprazole DrDexlansoprazole15$3,901
Celecoxib47$3,163
Atorvastatin Calcium254$2,660
Gabapentin147$2,420
Lacosamide13$1,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$61$69,02261 claims
Lilly USA, LLCTrulicity$46$54,27534 claims
Novo NordiskOzempic$63$49,53427 claims
MerckJanuvia$11$36,72933 claims
AstraZenecaFarxiga, Symbicort$212$23,71846 claims
GSKTrelegy Ellipta, Breo Ellipta$15$18,77233 claims
PfizerEliquis$13$17,07417 claims
AbbVieSynthroid$64$1,30412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,026 family providers in Oklahoma.

Other family in Enid

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →